ConductScience.org, home

Paper36722147

Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.

Bebia Z and 27 others. J Infect Dis, 2023. Cited by 56 papers, by iCite.

Cite this record

ConductScience Library. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial. Papers, record 36722147. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36722147

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.
PubMed
Journal
J Infect Dis
PubMed
Year
2023
PubMed
Publication types
Randomized Controlled Trial, Clinical Trial, Phase II, Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
56
iCite
Relative citation ratio, by iCite
6.8
iCite
Revised in PubMed
2023-08-16
PubMed

Authors28

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bebia ZZourab
2Reyes OOsvaldo
3Jeanfreau RRobert
4Kantele AAnuhttps://orcid.org/0000-0002-0004-1000
5De Leon RGRuth Graciela
6Sánchez MGMarta García
7Banooni PPeyman
8Gardener GJGlenn J
9Rasero JLBJosé Luis Bartha
10Pardilla MBEMaria Begoña Encinas
11Langley JMJoanne Mhttps://orcid.org/0000-0003-3270-7345
12Di Leo CMClaudio Maañón
13Botelho-Nevers EElisabethhttps://orcid.org/0000-0003-2773-7750
14Buttery JJim
15Laurichesse HHelene
16Madhi SAShabir A
17García AMAdrián Martín
18Stanley TThorsten
19Barjat TTiphaine
20Griffith RRebecca

Source PubMed

See all 28 authorsDownload CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Respiratory Syncytial Virus VaccinesMajor topic
Respiratory Syncytial Virus InfectionsMajor topic
Respiratory Syncytial Virus, HumanMajor topic
Pregnancy
Humans
Female
Infant
Infant, Newborn
Adolescent
Young Adult
Adult
Antibodies, Viral
Antibodies, Neutralizing
Mothers
Viral Fusion Proteins
Placenta
Immunogenicity, Vaccine

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT04126213
Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants
Derived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References20

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135942656Intrahepatic cholestasis of pregnancy: Green-top Guideline No. 43 June 2022.BJOG2022https://conductscience.org/library/papers/35942656PubMed
225070304Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.Pediatrics2014https://conductscience.org/library/papers/25070304PubMed
335598608Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.Lancet2022https://conductscience.org/library/papers/35598608PubMed
430107412Breast Milk Prefusion F Immunoglobulin G as a Correlate of Protection Against Respiratory Syncytial Virus Acute Respiratory Illness.J Infect Dis2019https://conductscience.org/library/papers/30107412PubMed
532463443Respiratory Syncytial Virus (RSV) Neutralizing Antibodies at Birth Predict Protection from RSV Illness in Infants in the First 3 Months of Life.Clin Infect Dis2021https://conductscience.org/library/papers/32463443PubMed
632726529Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants.N Engl J Med2020https://conductscience.org/library/papers/32726529PubMed
730913173Maternal Immunization.Obstet Gynecol2019https://conductscience.org/library/papers/30913173PubMed
817015575Diagnosis and management of bronchiolitis.Pediatrics2006https://conductscience.org/library/papers/17015575PubMed
927751641Global alignment of immunization safety assessment in pregnancy - The GAIA project.Vaccine2016https://conductscience.org/library/papers/27751641PubMed
1026070108Novel antigens for RSV vaccines.Curr Opin Immunol2015https://conductscience.org/library/papers/26070108PubMed
1124179220Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus.Science2013https://conductscience.org/library/papers/24179220PubMed
1223906887Research on vaccines during pregnancy: reference values for vital signs and laboratory assessments.Vaccine2013https://conductscience.org/library/papers/23906887PubMed
1334146100Three Dose Levels of a Maternal Respiratory Syncytial Virus Vaccine Candidate Are Well Tolerated and Immunogenic in a Randomized Trial in Nonpregnant Women.J Infect Dis2022https://conductscience.org/library/papers/34146100PubMed
1429308916Maternal immunization: where are we now and how to move forward?Ann Med2018https://conductscience.org/library/papers/29308916PubMed
1523325327Respiratory syncytial virus entry inhibitors targeting the F protein.Viruses2013https://conductscience.org/library/papers/23325327PubMed
1612850361Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women.Vaccine2003https://conductscience.org/library/papers/12850361PubMed
1731371616A proof of concept for structure-based vaccine design targeting RSV in humans.Science2019https://conductscience.org/library/papers/31371616PubMed
1831278106Prevalence and risk of pre-eclampsia and gestational hypertension in twin pregnancies: a population-based register study.BMJ Open2019https://conductscience.org/library/papers/31278106PubMed
1928574729Respiratory syncytial virus: prospects for new and emerging therapeutics.Expert Rev Respir Med2017https://conductscience.org/library/papers/28574729PubMed
2031402384Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants.J Infect Dis2019https://conductscience.org/library/papers/31402384PubMed

Download CSV of references

Cited by44

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 56 citations.

PMIDTitleJournalYearIn PapersSource
42827513Efficacy and safety of maternal RSV vaccination against infant lower respiratory tract infections: a systematic review and meta-analysis.Front Public Health2026https://conductscience.org/library/papers/42827513PubMed
42761810Maternal RSV vaccination: clinical efficacy, safety, and global policy considerations: a systematic review.J Pharm Policy Pract2026https://conductscience.org/library/papers/42761810PubMed
42712161RSV-Pre-F Vaccination During Pregnancy and Neonatal Outcomes-A Systematic Review and Meta-Analysis.Immun Inflamm Dis2026https://conductscience.org/library/papers/42712161PubMed
42523462CAUSAL-RSV: A study protocol for a causal mediation analysis of RSV vaccine effects in infants using real-world data.medRxiv2026https://conductscience.org/library/papers/42523462PubMed
42411551Delineating RSV-A and RSV-B: Epidemiological Patterns, Diagnostics, Clinical Severity, and Preventive Approaches.J Med Virol2026https://conductscience.org/library/papers/42411551PubMed
41975207The impact of maternal respiratory syncytial virus vaccination on infant and perinatal outcomes: a systematic review and meta-analysis of randomized controlled trials.J Perinatol2026https://conductscience.org/library/papers/41975207PubMed
41784331Introducing the Concept of Small Vulnerable Newborns (SVN) as an Additional Endpoint to Evaluate Birth Outcomes in the Context of RSV Immunization Studies-A Commentary.Influenza Other Respir Viruses2026https://conductscience.org/library/papers/41784331PubMed
41766205Randomized, placebo-controlled phase 3 trial evaluating safety, immunogenicity, and reactogenicity of RSVPreF3-Mat in high-risk pregnant women and their infants.Hum Vaccin Immunother2026https://conductscience.org/library/papers/41766205PubMed
41721455Maternal RSV immunization: clinical efficacy, immunological mechanisms and public health implications for preventing infant lower respiratory tract infection.J Health Popul Nutr2026https://conductscience.org/library/papers/41721455PubMed
41590244Real-World Evidence Evaluation of Respiratory Syncytial Virus (RSV) Vaccines: Deep Dive into Vaccine Adverse Events Reporting System.Diseases2026https://conductscience.org/library/papers/41590244PubMed
41455011Maternal RSV vaccine: a systematic review and meta-analysis of immunogenicity and perinatal safety.Immunol Res2025https://conductscience.org/library/papers/41455011PubMed
41395311Epidemiological characteristics and disease burden of childhood neuroblastoma in Asia: trends and regional differences over the past 30 years.Front Pediatr2025https://conductscience.org/library/papers/41395311PubMed
41295543Evaluation of the Safety and Efficacy of the Respiratory Syncytial Virus FG Chimeric Vaccine KD-409 in Rodent Models for Maternal and Pediatric Vaccination.Vaccines (Basel)2025https://conductscience.org/library/papers/41295543PubMed
41286483Position statement of the Mexican Association of Pediatrics on the immunoprevention of respiratory syncytial virus infection during pregnancy and infancy.World J Pediatr2026https://conductscience.org/library/papers/41286483PubMed
41221171Safety and efficacy of maternal RSV vaccination: a systematic review and meta-analysis.Clin Exp Vaccine Res2025https://conductscience.org/library/papers/41221171PubMed
40944041Epidemiological Changes in Pediatric RSV Infections in Poland (2016-2024): Impact of the COVID-19 Pandemic.J Clin Med2025https://conductscience.org/library/papers/40944041PubMed
40899087Natural Killer Cells Are Dispensable for Virus Control in Rag2-/- Mice During Primary RSV Infection.Eur J Immunol2025https://conductscience.org/library/papers/40899087PubMed
40821247Side Effects Associated With Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccination: A Scoping Review.Cureus2025https://conductscience.org/library/papers/40821247PubMed
40420998Respiratory syncytial virus: health burden, disease prevention, and treatment-recent progress and lessons learned.Microlife2025https://conductscience.org/library/papers/40420998PubMed
40240559Efficacy of monoclonal antibodies and maternal vaccination for prophylaxis of respiratory syncytial virus disease.Commun Med (Lond)2025https://conductscience.org/library/papers/40240559PubMed

See all 44 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36722147

GET https://conductscience.org/api/papers/v1/36722147/authors?page=2